Results 121 to 130 of about 1,374 (169)

The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica

Parasitology Research, 2004
Benzimidazole anthelmintics are widely used against nematode, cestode and trematode parasites. The drugs undergo several enzyme-mediated reactions within the host animal that produce a number of metabolites. Although it has been shown that certain helminths, including Fasciola hepatica, can metabolise albendazole, nothing is known regarding the ability
Hoey, Elizabeth, Robinson, Mark, Lawson, Jill, Trudgett, Alan, Fairweather, Ian   +4 more
openaire   +3 more sources

Protein Modelling and Molecular Docking Analysis of Fasciola hepatica β-Tubulin’s Interaction Sites, with Triclabendazole, Triclabendazole Sulphoxide and Triclabendazole Sulphone

Acta Parasitologica, 2023
Fasciola hepatica is a globally distributed trematode that causes significant economic losses. Triclabendazole is the primary pharmacological treatment for this parasite. However, the increasing resistance to triclabendazole limits its efficacy. Previous pharmacodynamics studies suggested that triclabendazole acts by interacting mainly with the β ...
Pamela Olivares-Ferretti, Jorge F. Beltrán, Luis A. Salazar, Flery Fonseca-Salamanca   +3 more
openaire   +2 more sources

Triclabendazole for the treatment of fascioliasis

Drugs of Today, 2019
Fascioliasis is a neglected tropical disease that is commonly caused by flatworms affecting both domestic ruminants and humans. Fascioliasis currently affects roughly 17 million people globally with additional 180 million people at risk of developing infection.
R, Thakare, A, Dasgupta, S, Chopra
openaire   +2 more sources

Diagnosis of resistance to triclabendazole

Veterinary Record, 2014
APART from several obvious reasons for failure of triclabendazole to control liver fluke infections, which can be summarised as misdosing, Fairweather (2011) suggested that reduced metabolism, as a result of liver damage, might be important. Following a serious incident of triclabendazole failure in central Wales, we would like to question how far ...
E M, Jones, R, Daniel, G C, Coles
openaire   +2 more sources

Chemoprophylaxis of fascioliasis with triclabendazole

New Zealand Veterinary Journal, 1985
In a field experiment, moderate to heavy natural concomitant infections with immature and mature Fasciola hepatica were treated with triclahendazole at a dose rate of 10 mg/kg and an efficiency of 99.8% was achieved. Subsequent treatments of all susceptible farm animals at the same dose rate at intervals of eight to eleven weeks were carried out for 14
J C, Boray, R, Jackson, M B, Strong
openaire   +2 more sources

Understanding triclabendazole resistance

Experimental and Molecular Pathology, 2007
Triclabendazole (TCBZ) has been the drug of choice to treat liver fluke infections in livestock for >20 years, due to its high activity against both adult and juvenile flukes. More recently, it has been used successfully to treat human cases of fascioliasis. Resistance to TCBZ first appeared in the field in Australia in the mid-1990s.
G P, Brennan, I, Fairweather, A, Trudgett, E, Hoey, , McCoy, M, McConville, M, Meaney, M, Robinson, N, McFerran, L, Ryan, C, Lanusse, L, Mottier, L, Alvarez, H, Solana, G, Virkel, P M, Brophy   +15 more
openaire   +3 more sources

Pharmacokinetics of triclabendazole in rabbits

Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, 1993
1. Pharmacokinetic profiles of triclabendazole (TCBZ) following intravenous (i.v.) and oral administration of the drug in rabbits were carried out. 2. In normal rabbits, TCBZ was metabolized rapidly to its sulphoxide (TCBZ-SO) and sulphone (TCBZ-SO2) derivatives following administration, with undetectable concentrations of unchanged TCBZ in the plasma ...
M L, Alvarez-Bujidos, A I, Ortiz, A, Negro, J C, Cubría, D, Ordóñez   +4 more
openaire   +2 more sources

The kinetics of triclabendazole disposition in sheep

Journal of Veterinary Pharmacology and Therapeutics, 1987
Hennessy, D.R., Lacey, E., Steel, J.W. & Prichard, R.K. The kinetics of triclabendazole disposition in sheep. J. vet. Pharmacol. Therap. 10, 64–72.To investigate whether the disposition of triclabendazole (TCBZ) and its metabolites in blood or bile influenced its flukicidal potency, TCBZ was administered intraruminally at 10 mg kg‐1 to sheep ...
D R, Hennessy, E, Lacey, J W, Steel, R K, Prichard   +3 more
openaire   +2 more sources

Anthelmintic Activity of Triclabendazole

Journal of Helminthology, 1986
Triclabendazole was tested in vitro and in vivo against a range of helminths. Although in vitro activity was found against Hymenolepis diminuta (0.5 microgram/ml), Fasciola hepatica (2.5 micrograms/ml), Taenia crassiceps and Schistosoma mansoni (50 micrograms/ml), in vivo activity was only found against F.
openaire   +2 more sources

Human fascioliasis successfully treated with triclabendazole

Australian and New Zealand Journal of Medicine, 1992
Abstract:Fascioliasis, caused by the common liver fluke Fusciolu hepatica, is an endemic infection in sheep and cattle in many parts of Australia. Infections in humans in Australia have been reported infrequently and the most appropriate therapy for human fascioliasis remains to be determined.
P P, Laird, J C, Boray
openaire   +2 more sources